Literature DB >> 33742349

Prenatal Neural Tube Anomalies: A Decade of Intrauterine Stem Cell Transplantation Using Advanced Tissue Engineering Methods.

Alireza Soltani Khaboushan1,2, Mehdi Shakibaei3, Abdol-Mohammad Kajbafzadeh4, Masoumeh Majidi Zolbin5.   

Abstract

Neural tube defects (NTDs) are among the most common congenital defects during neurulation. Spina bifida is a type of NTD that can occur in different forms. Since myelomeningocele (MMC) is the most severe form of spina bifida, finding a satisfactory treatment for MMC is a gold standard for the treatment of spina bifida. The Management of Myelomeningocele Study (MOMS) demonstrated that intrauterine treatment of spina bifida could ameliorate the complications associated with spina bifida and would also reduce the placement of ventriculoperitoneal (VP) shunt by 50%. Recently developed tissue engineering (TE) approaches using scaffolds, stem cells, and growth factors allow treatment of the fetus with minimally invasive methods and promising outcomes. The application of novel patches with appropriate stem cells and growth factors leads to better coverage of the defect with fewer complications. These approaches with less invasive surgical procedures, even in animal models with similar characteristics as the human MMC defect, paves the way for the modern application of less invasive surgical methods. Significantly, the early detection of these problems and applying these approaches can increase the potential efficacy of MMC treatment with fewer complications. However, further studies should be conducted to find the most suitable scaffolds and stem cells, and their application should be evaluated in animal models. This review intends to discuss advanced TE methods for treating MMC and recent successes in increasing the efficacy of the treatment.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Fetal treatment; Fetoscopy; Myelomeningocele; Open surgery; Scaffolds; Spina bifida; Stem cells; Tissue engineering

Mesh:

Year:  2021        PMID: 33742349     DOI: 10.1007/s12015-021-10150-w

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  67 in total

1.  Premiere use of Integra™ artificial skin to close an extensive fetal skin defect during open in utero repair of myelomeningocele.

Authors:  Martin Meuli; Claudia Meuli-Simmen; Alan W Flake; Roland Zimmermann; Nicole Ochsenbein; Ianina Scheer; Luca Mazzone; Ueli Moehrlen
Journal:  Pediatr Surg Int       Date:  2013-09-22       Impact factor: 1.827

2.  A tissue engineering approach for prenatal closure of myelomeningocele with gelatin sponges incorporating basic fibroblast growth factor.

Authors:  Miho Watanabe; Jun-ichiro Jo; Antonetta Radu; Michio Kaneko; Yasuhiko Tabata; Alan W Flake
Journal:  Tissue Eng Part A       Date:  2010-05       Impact factor: 3.845

3.  Trans-amniotic stem cell therapy (TRASCET) minimizes Chiari-II malformation in experimental spina bifida.

Authors:  Beatrice Dionigi; Joseph A Brazzo; Azra Ahmed; Christina Feng; Yaotang Wu; David Zurakowski; Dario O Fauza
Journal:  J Pediatr Surg       Date:  2015-03-14       Impact factor: 2.545

4.  Suture techniques and patch materials using an in-vitro model for watertight closure of in-utero spina bifida repair.

Authors:  Thai Vu; Lovepreet K Mann; Stephen A Fletcher; Ranu Jain; Jeannine Garnett; Kuojen Tsao; Mary T Austin; Kenneth J Moise; Anthony Johnson; Manish N Shah; Ramesha Papanna
Journal:  J Pediatr Surg       Date:  2019-06-19       Impact factor: 2.545

Review 5.  Tissue engineering strategies for fetal myelomeningocele repair in animal models.

Authors:  Miho Watanabe; Aimee G Kim; Alan W Flake
Journal:  Fetal Diagn Ther       Date:  2014-07-19       Impact factor: 2.587

Review 6.  Safety and efficacy of fetal surgery techniques to close a spina bifida defect in the fetal lamb model: A systematic review.

Authors:  Luc Joyeux; Felix De Bie; Enrico Danzer; Tim Van Mieghem; Alan W Flake; Jan Deprest
Journal:  Prenat Diagn       Date:  2018-02-28       Impact factor: 3.050

7.  In Vivo Evaluation of Novel PLA/PCL Polymeric Patch in Rats for Potential Spina Bifida Coverage.

Authors:  Marc Oria; Rigwed R Tatu; Chia-Ying Lin; Jose L Peiro
Journal:  J Surg Res       Date:  2019-05-06       Impact factor: 2.192

8.  Using poly(l-lactic acid) and poly(ɛ-caprolactone) blends to fabricate self-expanding, watertight and biodegradable surgical patches for potential fetoscopic myelomeningocele repair.

Authors:  Rigwed Tatu; Marc Oria; Sarah Pulliam; Lorenzo Signey; Marepalli B Rao; Jose L Peiro; Chia-Ying Lin
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2018-05-16       Impact factor: 3.368

9.  In Utero Amniotic Fluid Stem Cell Therapy Protects Against Myelomeningocele via Spinal Cord Coverage and Hepatocyte Growth Factor Secretion.

Authors:  Yushi Abe; Daigo Ochiai; Hirotaka Masuda; Yu Sato; Toshimitsu Otani; Marie Fukutake; Satoru Ikenoue; Kei Miyakoshi; Hideyuki Okano; Mamoru Tanaka
Journal:  Stem Cells Transl Med       Date:  2019-08-13       Impact factor: 6.940

10.  Long term trends in prevalence of neural tube defects in Europe: population based study.

Authors:  Babak Khoshnood; Maria Loane; Hermien de Walle; Larraitz Arriola; Marie-Claude Addor; Ingeborg Barisic; Judit Beres; Fabrizio Bianchi; Carlos Dias; Elizabeth Draper; Ester Garne; Miriam Gatt; Martin Haeusler; Kari Klungsoyr; Anna Latos-Bielenska; Catherine Lynch; Bob McDonnell; Vera Nelen; Amanda J Neville; Mary T O'Mahony; Annette Queisser-Luft; Judith Rankin; Anke Rissmann; Annukka Ritvanen; Catherine Rounding; Antonin Sipek; David Tucker; Christine Verellen-Dumoulin; Diana Wellesley; Helen Dolk
Journal:  BMJ       Date:  2015-11-24
View more
  1 in total

Review 1.  Decellularization in Tissue Engineering and Regenerative Medicine: Evaluation, Modification, and Application Methods.

Authors:  Afarin Neishabouri; Alireza Soltani Khaboushan; Faezeh Daghigh; Abdol-Mohammad Kajbafzadeh; Masoumeh Majidi Zolbin
Journal:  Front Bioeng Biotechnol       Date:  2022-04-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.